Showing 3351-3360 of 9946 results for "".
Prospective Analysis: PRP Post-Mohs; Physician Debt Insights
https://practicaldermatology.com/youngmd-connect/resident-resource-center/propsective-analysis-prp-post-mohs-physician-debt-insights/23038/New OTC Topicals Target Hyperpigmentation, Melasma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-otc-topicals-target-hyperpigmentation-melasma/22081/There's a new and expanding menu of options to improve uneven tone, proving that OTCs can provide benefit for a vexing concern.A Novel Therapeutic Option for the Treatment of Molluscum Contagiosum
https://practicaldermatology.com/topics/general-topics/a-novel-therapeutic-option-for-the-treatment-of-molluscum-contagiosum/21040/There is no FDA approved treatment for molluscum. A novel intervention may erradicate Molluscum with one treatment.DermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-17/23343/Aerolase’s Neo Elite 650-Microsecond 1064nm Laser: A New Option for the Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/aerolases-neo-elite-650-microsecond-1064nm-laser-a-new-option-for-the-treatment-of-psoriasis/23204/Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobLyme Disease Update
https://practicaldermatology.com/topics/general-topics/lyme-disease-update/20604/Exploring current thinking about Lyme Disease diagnosis and treatment.Managing Pruritus in Geriatric Patients
https://practicaldermatology.com/topics/practice-management/managing-pruritus-in-geriatric-patients/21146/Treatment tips and considerations for this patient population.The Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.